Cargando…
Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium ((89)Zr)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for (89)Zr-immuno-PET is low tumor contrast. This is expected to...
Autores principales: | Jauw, Yvonne W. S., Bensch, Frederike, Brouwers, Adrienne H., Hoekstra, Otto S., Zijlstra, Josée M., Pieplenbosch, Simone, Schröder, Carolien P., Zweegman, Sonja, van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien, de Vries, Elisabeth G. E., de Vet, Henrica C. W., Boellaard, Ronald, Huisman, Marc C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647131/ https://www.ncbi.nlm.nih.gov/pubmed/31209514 http://dx.doi.org/10.1007/s00259-019-04377-6 |
Ejemplares similares
-
Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021) -
Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018) -
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016) -
Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022) -
3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)